INTRODUCTION
With the aging of the population of HIV-infected individuals because of combined antiretroviral therapy (cART), the landscape of malignancies has shifted. Classical AIDS-defining malignancies (ADM) have decreased; however, other non-AIDSdefining malignancies (NADMs) such as anal, lung, colorectal, and liver cancers continue to pose a significant health threat to patients with HIV [1 & ,2]. Women with HIV continue to be affected by gynecological and nongynecological cancers at alarming rates. Cervical cancer caused by human papillomavirus (HPV) continues to cause a significant burden of cancer and cancer-related deaths especially in resource-limited setting such as subSaharan Africa (SSA) [3] . Anal cancer has historically been a focus for men with HIV, especially those who have sex with men. However, anal cancer, another HPV-mediated state, has increasingly been recognized as a major health threat to women [4 && ]. Herein, we review the following malignancies currently affecting women with HIV: cervical cancer, anal cancer, breast cancer, ovarian and uterine cancer, lung cancer, non-Hodgkin lymphoma (NHL), and Kaposi's sarcoma. Available research of colorectal and liver cancer indicates that HIV-infected women are less affected by these malignancies compared to HIV-infected men, and will not be included in detail in this review [5] [6] [7] [8] .
CERVICAL CANCER
Among reproductive malignancies, invasive cervical cancer (ICC) is the number one cause of new cancers in women and responsible for the most deaths in women world-wide [3] . Women residing in resource-limited settings bear the brunt of this disease with incidence rates greater than 30.2/100 000 population compared to more industrialized nations where incidence rates are much lower, less than 7.9/100 000 population [3] . In the United States where incidence is relatively low, cervical cancer in HIV-infected women the incidence still remains 66% higher than women without HIV [9] . However, in some areas of SSA, ICC incidence is much higher, nearly 168/100 000 women on cART [10] . Mortality from ICC has continued to be higher in HIV-infected women than HIV-uninfected women. Although mortality is not statistically significant in resource rich settings [2] , women living in resource-limited setting, suffer disproportionate mortality. For instance, in SSA mortality is greater than 17.5/100 000 population, more than three-fold the morality of cervical cancer in the United States [3] .
HIV-infected women are known to be at high risk for HPV infection, the virus responsible for genital warts, precancerous lesions, and ICC [11] . Globally, infection with one or multiple types of HPV virus, including high-risk HPV (hrHPV) strains, in HIV-infected women is common and as high as 91% in some SSA regions [12,13 & ]. In SSA, the six most common types of HPV are oncogenic types 16, 18, 35, 45, 33, and 52 [14] . Immunologic and virologic HIV control are significant cofactors in the persistence, and progression of HPV infection to premalignant lesions and ICC [11, 15, 16] . The use of cART, however, may not completely reverse the oncogenic potential of HPV especially if early malignant changes begin to take place while CD4 counts are low [15] .
Clinical presentation of ICC in women with HIV often occurs at younger ages, up to 15 years earlier in advanced HIV compared with HIV-uninfected women [17, 18] , which may suggest a shorter latency period in HIV-infected women. Some studies have described women with HIV presenting with later, more advanced stage ICC than HIV-uninfected women [17] ; however, other studies have found high rates of advanced ICC in both HIV-infected and HIV-uninfected populations alike in resource limited settings [19] , suggesting the pervasive lack of cervical cancer screening.
Cervical cancer histology is most commonly squamous cell carcinoma (SCC), and treatment includes surgery, chemotherapy, and/or radiation [17, 19] . Treatment is challenging in many resource limited countries lacking appropriate facilities and equipment [20] . Treatment interruptions and incomplete cancer therapy have significant affects upon cancer outcomes, and women with HIV infection are at high risk of having residual tumor burden [18] . Interestingly, women treated with cART have higher likelihood of treatment completion [19] , likely owing to improved treatment tolerance.
Screening for cervical cancer is a key component of primary care for women with HIV. However, wide spread cytology screening and hrHPV detection in low-income countries is difficult to implement because of lack of adequate facilities, resources, finances, and trained personnel, however [21] . The WHO has adopted an alternative approach using the 'screen-and-treat' method for resourcelimited settings. This encourages use of available screening methods, preferably HPV testing as first line, followed by immediate treatments (e.g. cryotherapy) for cervical abnormalities [22] . HPV testing in low-resource, high burden settings may be desirable because of its sensitivity for detecting precancerous lesions as well as its convenience for selftesting [23, 24] ; however, cost-effectiveness may preclude its widespread use [10] .
Cervical cancer is a now a vaccine preventable disease. Widespread vaccination for HPV is critical in young girls and women with HIV in low-income and high-income settings alike. Most recently, the nonovalent vaccine, containing a broader coverage of cancer-causing strains (additional types 31, 33, 35, 52, 58) , was added to the armamentarium [25] . These are recommended for routine vaccination of females ages 11-26 years [26, 27] . Immunogenicity of the quadrivalent and bivalent vaccines in women with HIV but without evidence of HPV infection is good (>75%); however, like other vaccines in HIVinfected persons, robust CD4 counts confer better seroconversion response [28] . In 2014, only 58 countries had incorporated HPV vaccination into national immunization campaigns and mostly in high-income settings [27] . More recently, countries in SSA have begun to implement HPV vaccination nationwide with support from global health programs [29] , which may have significant cost efficacy [30] . Unfortunately, the details of real-world vaccination uptake in HIV-infected girls and women remain difficult to accomplish [31] .
KEY POINTS
Cervical cancer disproportionately affects women with HIV likely because of high prevalence and persistence of HPV infection.
Lack of primary prevention programs, screening infrastructure, and treatment resources have contributed to high mortality in low-income countries.
HPV vaccination has been shown to be beneficial and cost-effective in preventing cervical and anal cancer in women.
Treating underlying HIV with cART is a critical component of cancer prevention, treatment, and survival for HIV-infected women with cancer.
ANAL CANCER
Most anal cancers are composed of SCC and associated with the presence of hrHPV types in 90% of cases [32] . Incidence of anal SCC has continued to increase globally, and in developed countries incidence has increased 1-3% annually [32] . In the United States, women are affected more than men with a rate of 1.8 versus 1.1/100 000 population [33] . Incidence of anal cancer in HIV-infected women in higher income countries is also high (3.9-30 per 100 000) [ ; moreover, increased risk of HPV-associated neoplasia has been associated with increased duration after AIDS diagnosis [34, 35] . Immunosuppression may facilitate early viral-mediated oncogenesis, which is irreversible despite CARTmediated immune restoration [34] . Interestingly, HIV viral load has not been associated with the presence of abnormal anal cytologic findings in HIV-infected women [4 && ], but has been associated with an increased number of high-grade squamous intraepithelial lesions and anal condyloma [36, 37] .
Practice of anal cancer screening using anal canal Dacron swab technique and liquid cytological evaluation has derived from cervical cytology testing. Classifying cellular histology of anal lesions also employs the revised Bethesda System for Reporting Cervical Cytology [38, 39] . Sensitivity of detecting high-grade anal neoplasia ranges from 69 to 93% in several studies [38] , and abnormal anal cytology should be further investigated with high-resolution anoscopy (HRA), which is analogous to the cervical colposcopy [40, 41] . HPV DNA testing is controversial given the high prevalence of hrHPV viral infection in HIV-infected persons [39, 42] . However, presence of hrHPV genotype 16 is associated with concurrent high-grade anal lesions in women with HIV [43, 44] .
Because of lack of standardized guidelines on anal cancer screening, clinicians have been charged with creating local protocols to address this need. Determining which women are at high risk for anal cancer is of the utmost importance. Women with a history of cervical or vulvar neoplasias are more likely to have anal HPV-infection and abnormal anal cytology [4 && ,43] . The presence of anal warts or condyloma acuminata may also be an indicator for HPV infection of the anal canal and may warrant further screening. A limitation of implementing anal cancer screening beyond a yearly digital rectal exam is the lack of readily accessible and trained personnel and equipment for performing HRA. If HRA is not available, anal cytology is discouraged [45] .
Primary prevention of anal cancer has been more extensively studied in men because of high incidence rates of anal cancer in men who have sex with men (MSM). Women receiving the latest nonovalent HPV vaccine could potentially reap significant benefit and reduction of up to 87% of anogenital cancers globally [46 & ]. Anal cancer prevention is an added benefit of early HPV vaccination in girls and women with HIV or in areas with highendemic rates of HIV and HPV infection.
BREAST CANCER
Breast cancer remains the most common cancer type (23% of total new cancer cases) in women living in industrialized and nonindustrialized countries [3] . It also is the most common cause of cancer-related deaths among women, accounting for 15% of total cancer deaths [3] . Breast cancer has previously been described as occurring less frequently in women with AIDS compared to the general population [47] [48] [49] . One large retrospective United States study of women with AIDS followed for 665 987 person years (PYs) showed a SIR 0.69 (95% CI, 0.62-0.77); however, increases over the follow-up period of locally/regionally disseminated disease approached that of the general population [50] .
As HIV-infected women age, the incidence of breast cancer is likely going to increase. Previous case series have demonstrated that women present at younger ages, frequently with advanced disease, increased multifocality of disease, early metastasis, and poor outcomes [51] [52] [53] . Prior studies have not demonstrated significant association with low CD4 counts or AIDS diagnoses with the development of breast cancer [53] . The links between HIV, the immune response, and natural history of breast cancer are unclear based on the limited, available data. Larger studies are needed to identify HIVspecific risk factors in the acquisition and progression of breast cancer.
Breast cancer treatment in HIV-infected women remains challenging because chemotherapeutic agents can also pose significant drug interactions with antiretroviral therapies. Standard guidelinebased therapies based on stage at diagnosis should be implemented for eligible HIV-infected women [53] . Rates of estrogen, progesterone, or HER-2/ neu receptor status of breast tumors in HIV-infected women are not well established, but estrogen receptor positivity has been reported in nearly 50% of cases [53, 54] . Close attention should be paid to drug interactions between breast cancer therapies, including hormonal therapies and antiretroviral therapies. Cancer-specific mortality in women with HIV in the post-cART era remains higher than in the general population [hazard ratio (HR) 3.43; 95% CI, 2.35-5.01] [2] . In one case series, progression-free survival at 5 years was 50% and median overall survival was 52 months [53, 54] .
Screening and prevention of breast cancer are of the utmost importance in women with HIV infection. Current United States Preventive Service Task Force screening guidelines recommend for the general population biennial mammography for women ages 50-74; however, more frequent screening can be used in patients who may be at increased risk [55] . For HIV-infected women, this level of screening is the acceptable practice [56] until further risk factors (e.g. HIV-specific or genetic markers) beyond family history can be firmly established and in practice to better identify women at high risk for breast cancer. Despite these recommendations, screening for breast cancer in women with HIV remains challenging with historically low screening rates (30-50%) compared with the general population [57, 58] .
OVARIAN AND UTERINE CANCER
Uterine and ovarian cancers account for about 4% of new cancer diagnoses in women [59, 60] . Although relatively less common, ovarian malignancies are responsible for a large burden of annual deaths (age-standardized rate 3.8%) with poor survival often less than 50% when compared to other gynecological cancers [3, 59] .
Only few studies have characterized ovarian and uterine cancers in women with HIV infection. Interestingly, one large study following 85 268 women for 665 987 PYs found significantly lower incidence of uterine cancer compared with the general population with only 31 cases (SIR 0.57; 95% CI, 0.39-0.81) [50] . After stratifying groups based on menopausal status, women less than 50 years had a uterine cancer SIR 0.86 (05% CI, 0.54-1.32), and women greater than 50 years had a SIR of 0.33 (95% CI, 0.4-1.68). Within this same study only 42 cases of ovarian cancer were identified (SIR 1.05; 95% CI, 0.75-1.42) [50] . With regard to immune status, there was also no significant relationship between onset of AIDS diagnosis or CD4 count for uterine or ovarian cancer. However, infertility and poor ovarian function are also more common in women with HIV than in the general population [61] ; thus, the impact of HIV infection upon ovarian cancer development is unclear.
Data on mortality because of ovarian and uterine cancers specifically in the HIV population are limited likely because of the relative infrequency of these cancers. One Italian study, mortality from uterine cancer accounted for 4% of cancer-specific deaths from 2006 to 2011 [62] . Standardized mortality ratio of women with AIDS and uterine cancer was 52.5 (95% CI, 14.3-134.5) compared to those without AIDS in the same study [62] .
LUNG CANCER
Lung cancer, primarily non-small cell lung cancer (NSCLC), is a leading cause of cancer death among persons with HIV infection and poses a major threat to morbidity and mortality in the HIV population globally [2, 62] . Over time from the precART era to postcART, the number of lung cancer cases has risen more than two-fold in the United States, especially in people greater than 50 years, which is likely because of both high rates of tobacco use and aging in the HIV-infected population [63] . Even after carefully controlling for smoking prevalence, HIV itself has been described as an independent risk factor for lung cancer [64] , and women with HIV have nearly four-fold higher incidence than the general population [65] . Recurrent bacterial pneumonias among persons with HIV also has been implicated as a risk factor for lung cancer development because of persistent tissue inflammation [66] . Mortality continues to remain higher among patients with HIV in the post-cART era compared to HIV-uninfected patients (HR 1.38; 95% CI, 1.21-1.56) [2] .
Lung cancer patients with HIV tend to present at younger ages (54.1 vs. 60.5 years) compared to those without HIV, and a South African study found no statistical sex difference between HIV-infected and uninfected lung cancer cases [67 & ,68] . Several studies have found that HIV-infected patients commonly present with advanced disease (stage III/IV) [64,67 & ,68,69] . In addition, HIV-infected patients with NSCLC have worse 5-year overall survival compared to those without HIV (9 vs. 23%) [70] . Robust CD4 count (>200 cells/mL) carry improved survival compared to those with low CD4 counts (median survival 11.5 months compared to 3.4 months) [68] .
Tobacco smoking prevalence among HIVinfected men and women is significant with rates nearly two to three times higher than in the general population [71, 72] . Among persons with HIV and lung cancer, current smokers (aIRR 6.3; 95% CI, 4.7-8.4) and former smokers (aIRR 3; 95% CI 2.2-4.1) have higher risk of lung cancer than never smokers [64] . Tobacco smoking cessation should be a key component of primary care and for lung cancer prevention for HIV-infected women, pharmacologic-aides may be useful during cessation attempts [73] .
Because of improved mortality benefit, lung cancer screening with low-dose computed tomography (LDCT) is recommended for people aged in the general population with at least a 30 pack-year smoking history and currently smoke or who have quit within 15 years, regardless of gender [74] . Some caution must be taken in screening HIV-infected patients, especially those with poor CD4 count, as they are likely to have false positive LDCT findings because of prior lung infections [75] . These may lead to unnecessary testing, surgery, and patient anxiety.
NON-HODGKIN LYMPHOMA
The postcART era has experienced an overall decline in incidence of NHL; however, incidence of NHL among HIV-infected persons continues to be significantly higher (>10-fold) than the general popu- 76] . Gender-specific incidence rates of NHL favor women, who have a lower incidence of this malignancy across high and low-income regions. French and Swiss data have shown fewer HIV-infected women are at risk of acquiring NHL compared to HIV-infected men (16 vs. 18%, respectively) [5, 65] . In Southeast Asia, North Africa, and SSA, NHL affects women less than men as well [76] .
NHL remains the largest cause death among the ADMs [2, 62, 77] ; however, NHL-specific death in the postcART era affects women much less frequently than men (3-22 vs. 15.2-78%, respectively) [77, 78] . Furthermore, with the widespread implementation of cART, 5-year survival across genders has improved dramatically compared to pre-cART eras in France (65 vs. 15% 5-year survival, respectively) and in the United States (54-9% 5-year, respectively) [5, 78] . In addition, increased uptake of standard, more doseintensive chemotherapeutic treatment strategies has helped improve complete remission and survival rates in the HIV-infected population regardless of low CD4 counts and AIDS diagnoses [79, 80] .
KAPOSI'S SARCOMA
Human herpesvirus-8 (HHV-8) infection has a significant geographic variance ranging from 1 to 8% in Western nations and 40 to 80% in SSA [81] . People with HIV infection are more likely (OR 1.99; 95% CI, 1.7-2.34) to have HHV-8 infection than the general population [82] . This parallels the trends of AIDS-related Kaposi's sarcoma, and in the United States, for example, the incidence of Kaposi's sarcoma within the HIV population is exceedingly high compared to the general population (130/ 100 000 vs. 0.2/100 000 PYs, respectively
HIV-infected men carry the largest burden of these conditions among persons with HIV because of the high prevalence of HHV-8 infection among MSM [83] . A recent systematic review comparing HHV-8 prevalence between men and women found that after excluding studies with MSM, heterosexual men in SSA had a increased risk of HHV-8 infection (OR 1.21; 95% CI, 1.09-1.34), but this was not true for men from other localities [84 & ]. In resource-rich countries, Kaposi's sarcoma represents a small fraction (2-3%) of all ADM in women [5, 85, 86] ; however, in low-income regions such as SSA, incidence of Kaposi's sarcoma in women with HIV seems to be elevated, especially in untreated groups (1214/100 000 PYs) [87] .
Comprehensive data on clinical presentation of Kaposi's sarcoma in women are limited; however, women may present at younger ages (second and third decades) and may have more disseminated skin disease compared to men [88, 89] . Treatment of HIV with cART is the cornerstone of prevention and treatment of Kaposi's sarcoma owing to improved immunological control [90] . In addition, systemic chemotherapeutic agents such as taxanes and anthracyclines for progressive Kaposi's sarcoma may be beneficial [91] .
Survival data in women compared to men are mixed in studies from SSA regions. Furthermore, treatment outcomes specifically for HIV-infected women are limited likely because of lower burden of disease in this gender class, especially in Western regions. In one small study from Uganda, sex was not a risk factor for Kaposi's sarcoma-associated mortality [92] . However, another study from South Africa found women were twice as likely to die from Kaposi's sarcoma compared to their male counterparts [87] .
CONCLUSION
At the cornerstone of all prevention strategies for cancer in HIV-infected women is engagement in healthcare and effective treatment with cART. Cancer prevention is critical to curb morbidity and mortality in HIV-infected women, especially because many neoplastic states present at younger ages and at more advanced stages than in the general population. In addition, HIV-infected women are especially at risk for HPV-mediated disease because of persistent HPV infection, especially in low-income settings with high HPV infection prevalence. Thus, primary prevention with vaccination strategies for HPV-related neoplasias is of utmost importance. Furthermore, implementation, access, and affordability of breast and lung cancer screening are also key components for decreasing cancer morbidity and mortality among HIV-infected women. Finally, differences in the incidence and mortality of nonfemale-specific cancers, such as colorectal, liver, Kaposi's sarcoma, and lymphoma are needed to better clarify the potential effect of gender-specific differences, including sex hormones and other sexspecific biologic and behavioral risk factors on the incidence and outcomes of these cancers in HIVinfected women.
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